Connect with us

Hi, what are you looking for?

Jewish Business News

Court

Teva Petitions US Supreme Court Over Copaxone Ruling

Teva expects the Supreme Court to hear the case in April, a month before the Copaxone patents expire.
images

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has asked the US Supreme Court to review a lower court ruling in July 2013 that invalidated some of the patents for its multiple sclerosis drug Copaxone.

The patents expire in May.

Teva expects the Supreme Court to hear the case in April, a month before the Copaxone patents expire. However, the Supreme Court is unlikely to overturn the ruling by the Federal Circuit of Appeals. In November 2013, the Supreme Court rejected Teva’s motion to put a lower court ruling on hold while it decides on Teva’s appeal.

Although Copaxone’s patents expire in May, companies developing generic versions of the drug will not be able to market them before obtaining approval from the US Food and Drug Administration (FDA).

Published by Globes [online], Israel business news – www.globes-online.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış cialis